[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3315
81. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, Yang B: The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res; 2007;9(4):R47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis.
  • INTRODUCTION: Increased versican expression has been associated with local breast cancer invasiveness and a more aggressive tumor phenotype.
  • The cellular mechanisms are not fully understood and this study evaluated versican G3 domain with its EGF-like motifs in influencing tumor invasion and metastasis.
  • In vivo study of tumor growth was evaluated in a nude mouse model.
  • An intracardiac injection model of metastatic human breast carcinoma tested the effect of G3 on distant bony and soft tissue metastasis.
  • Analysis of metastatic burden included histology, radiographs, and micro-CT quantification of osteolysis.
  • RESULTS: A greater viability of cancer cells was observed in low serum and serum-free conditions in the presence of versican G3.
  • Larger subcutaneous tumors were obtained in the G3 group following tumor cell injection into CD1 mice.
  • Systemic tumor burden to distant bony and soft tissue metastatic sites was greater in the G3 group using the intracardiac injection metastatic model.
  • CONCLUSION: Versican G3 domain appears to be important in local and systemic tumor invasiveness of human breast cancer.
  • Effects include enhancing cell viability, proliferation, migration and enhancing local tumor growth.
  • The interactions between tumor cells, surrounding stromal components and neo-vascularization in breast cancer may include interactions with VEGF and fibronectin.
  • The propensity of versican G3 to influence tumor invasion to bone and the mechanisms of G3 mediated osteolysis warrants ongoing studies.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Versicans / pharmacology
  • [MeSH-minor] Animals. Cell Adhesion. Cell Line, Tumor. Cell Proliferation. Chickens. Endothelium, Vascular / drug effects. Female. Fibronectins / metabolism. Fibronectins / pharmacology. Humans. Mice. Mice, Nude. Neoplasm Invasiveness. Neovascularization, Pathologic / pathology. Osteolysis. Protein Structure, Tertiary. Transfection. Vascular Endothelial Growth Factor A / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35448-56 [10950950.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jan;454:230-6 [16924176.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14178-86 [11297534.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12294-301 [11805102.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12921-30 [11821431.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1054-60 [11948113.001]
  • [Cites] Circ Res. 2002 Jul 12;91(1):25-31 [12114318.001]
  • [Cites] J Pathol. 2003 Apr;199(4):479-87 [12635139.001]
  • [Cites] Am J Clin Pathol. 2003 Apr;119(4):587-93 [12710131.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3626-31 [12839951.001]
  • [Cites] Life Sci. 2003 Nov 14;73(26):3399-413 [14572881.001]
  • [Cites] FASEB J. 2004 Apr;18(6):754-6 [14766798.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2491-8 [15073129.001]
  • [Cites] J Cell Sci. 2004 May 1;117(Pt 11):2227-37 [15126624.001]
  • [Cites] J Comp Pathol. 2004 Nov;131(4):259-70 [15511534.001]
  • [Cites] J Biol Chem. 1986 Oct 15;261(29):13517-25 [3759975.001]
  • [Cites] J Biol Chem. 1986 Oct 15;261(29):13526-35 [3759976.001]
  • [Cites] J Biol Chem. 1989 May 15;264(14):8012-8 [2470739.001]
  • [Cites] EMBO J. 1989 Oct;8(10):2975-81 [2583089.001]
  • [Cites] J Biol Chem. 1993 Jul 5;268(19):14461-9 [8314802.001]
  • [Cites] J Cell Sci. 1993 Sep;106 ( Pt 1):55-65 [8270643.001]
  • [Cites] J Cell Biol. 1993 Dec;123(6 Pt 2):1899-907 [8276905.001]
  • [Cites] J Cell Biol. 1994 Mar;124(5):817-25 [8120102.001]
  • [Cites] J Biol Chem. 1994 Dec 30;269(52):32999-3008 [7528742.001]
  • [Cites] J Cell Sci. 1994 Sep;107 ( Pt 9):2581-90 [7531202.001]
  • [Cites] Eur J Neurosci. 1995 Apr 1;7(4):805-14 [7620627.001]
  • [Cites] J Histochem Cytochem. 1996 Apr;44(4):303-12 [8601689.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 May;55(5):528-33 [8627343.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3902-8 [8752156.001]
  • [Cites] Histochem J. 1997 Jan;29(1):21-30 [9088942.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):963-71 [9563891.001]
  • [Cites] Int Immunol. 1999 Mar;11(3):393-405 [10221651.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1041-56 [10353737.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jun;58(6):597-605 [10374750.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):219-25 [10389756.001]
  • [Cites] Matrix Biol. 1999 Aug;18(4):343-55 [10517181.001]
  • [Cites] Oncologist. 2004;9(6):606-16 [15561805.001]
  • [Cites] Cell Res. 2005 Jul;15(7):483-94 [16045811.001]
  • [Cites] Histochem Cell Biol. 2005 Aug;124(2):139-49 [16088379.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1553-62 [15983115.001]
  • [Cites] Cancer Lett. 2006 Feb 8;232(2):123-38 [16458110.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R20 [16608535.001]
  • [Cites] Lab Invest. 2006 Sep;86(9):889-901 [16847433.001]
  • [Cites] Int J Gynecol Cancer. 2006;16 Suppl 2:543-8 [17010069.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):181-8 [17036319.001]
  • [Cites] Exp Cell Res. 2001 Feb 1;263(1):33-42 [11161703.001]
  • (PMID = 17662123.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; 126968-45-4 / Versicans
  • [Other-IDs] NLM/ PMC2206723
  •  go-up   go-down


82. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • Two patients developed bone metastases.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


83. López-O'Rourke VJ, Orient-López F, Fontg-Manzano F, Fernández-Mariscal E, Combalía A, Vilarrasa-Sauquet R, Sañudo-Martín I: Pathological vertebral compression fracture of C3 due to a breast cancer metastasis in a male patient. Spine (Phila Pa 1976); 2009 Jul 15;34(16):E586-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological vertebral compression fracture of C3 due to a breast cancer metastasis in a male patient.
  • STUDY DESIGN: A case of vertebral body fracture due to metastatic breast cancer in a male patient and a review of the literature are presented.
  • OBJECTIVE: To draw attention to the possible adverse skeletal events in breast cancer patients, and the need of a watchful staff within the multidisciplinary team in charge.
  • SUMMARY OF BACKGROUND DATA: Breast cancer is a rare condition in men, the male/female ratio is 1 of 100 approximately; in both sexes bone metastases are the most common.
  • The pathologic fracture by spinal metastases can cause intense pain with difficult management.
  • Vertebroplasty has been used successfully to treat pain and improve functional status in patients with vertebral compression fractures due to metastases.
  • METHODS: A 43-year-old male patient was diagnosed of having breast epithelial carcinoma after histologic analysis of a femur fracture.
  • In a control visit, he referred sudden cervical pain which was initially treated with nonsteroidal anti-inflammatory drugs and rest.
  • The patient was seen in a later visit and complained about poor response to analgesia.
  • For this reason, a radiologic study was carried out, showing signs of fracture of the third cervical vertebral body (C3), and was completed with magnetic resonance imaging where the diagnosis of osteolytic metastasis was confirmed.
  • CONCLUSION: Spinal metastases treatment may include combinations of radiotherapy, vertebroplasty, and bisphosphonates, which have proved analgesic effect and a decrease of bone complications; however, out of these options, only vertebroplasty allows rapid stabilization and analgesia.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Cervical Vertebrae / surgery. Fractures, Compression / surgery. Spinal Neoplasms / secondary


8
Advertisement
4. Boukhechba F, Balaguer T, Michiels JF, Ackermann K, Quincey D, Bouler JM, Pyerin W, Carle GF, Rochet N: Human primary osteocyte differentiation in a 3D culture system. J Bone Miner Res; 2009 Nov;24(11):1927-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human primary osteocyte differentiation in a 3D culture system.
  • Studies on primary osteocytes, which compose >90-95% of bone cells, embedded throughout the mineralized matrix, are a major challenge because of their difficult accessibility and the very rare models available in vitro.
  • These 3D-differentiated osteocytes were compared with 2D-cultured cells and with human microdissected cortical osteocytes obtained from bone cryosections.
  • Osteocyte differentiation was assessed by histological and immunohistological analysis after paraffin embedding of culture after various times, as well as by quantitative RT-PCR analysis of a panel of osteoblast and osteocyte markers after nucleic acid extraction.
  • Real-time PCR expression of a set of bone-related genes confirmed their osteocyte phenotype.
  • Comparison with plastic-cultured cells and mature osteocytes microdissected from human cortical bone allowed to assess their maturation stage as osteoid-osteocytes.
  • It should be a suitable method to study the osteoblast-osteocyte differentiation pathway, the osteocyte interaction with the other bone cells, and orchestration of bone remodeling transmitted by mechanical loading and shear stress.
  • It should be used in important cancer research areas such as the cross-talk of osteocytes with tumor cells in bone metastasis, because it has been recently shown that gene expression in osteocytes is strongly affected by cancer cells of different origin.
  • It could also be a very efficient tool for drug testing and bone tissue engineering applications.
  • [MeSH-minor] Biomarkers / metabolism. Bone Morphogenetic Proteins / genetics. Bone Morphogenetic Proteins / metabolism. Bone and Bones / cytology. Bone and Bones / drug effects. Bone and Bones / metabolism. Calcium Phosphates / pharmacology. Cells, Cultured. Ceramics / pharmacology. Gene Expression Profiling. Gene Expression Regulation / drug effects. Genetic Markers / genetics. Humans. Immunohistochemistry. Microdissection. Parathyroid Hormone / pharmacology. Plastics. RANK Ligand / genetics. RANK Ligand / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419324.001).
  • [ISSN] 1523-4681
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Bone Morphogenetic Proteins; 0 / Calcium Phosphates; 0 / Genetic Markers; 0 / Parathyroid Hormone; 0 / Plastics; 0 / RANK Ligand; 0 / SOST protein, human; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


85. Russell RG: Bisphosphonates: mode of action and pharmacology. Pediatrics; 2007 Mar;119 Suppl 2:S150-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The profound effects of the bisphosphonates on calcium metabolism were discovered over 30 years ago, and they are now well established as the major drugs used for the treatment of bone diseases associated with excessive resorption.
  • Their principal uses are for Paget disease of bone, myeloma, bone metastases, and osteoporosis in adults, but there has been increasing and successful application in pediatric bone diseases, notably osteogenesis imperfecta.
  • Bisphosphonates inhibit bone resorption by selective adsorption to mineral surfaces and subsequent internalization by bone-resorbing osteoclasts where they interfere with various biochemical processes.
  • Although bisphosphonates are now established as an important class of drugs for the treatment of many bone diseases, there is new knowledge about how they work and the subtle but potentially important differences that exist between individual bisphosphonates.
  • [MeSH-major] Bone Density Conservation Agents / pharmacology. Diphosphonates / pharmacology
  • [MeSH-minor] Adult. Animals. Bone Diseases / drug therapy. Calcification, Physiologic / drug effects. Child. Drug Administration Routes. Drug Administration Schedule. Drug Evaluation. Humans. Osteoclasts / drug effects. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17332236.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  • [Number-of-references] 155
  •  go-up   go-down


86. Simeone AM, Colella S, Krahe R, Johnson MM, Mora E, Tari AM: N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells. Carcinogenesis; 2006 Mar;27(3):568-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.
  • Breast cancer most frequently metastasizes to bone causing decreased quality of life and morbidity.
  • Since current treatments are palliative, strategies to prevent bone metastases in breast cancer patients are required.
  • There is substantial evidence indicating that high levels of nitric oxide (NO) suppress tumor growth and metastasis in vivo.
  • We hypothesize that agents that produce high concentrations of NO could prevent the spread of breast cancer to bone.
  • The objective of this study was to determine the effectiveness of 4-HPR and an NO pro-drug, diethylamineNONOate/AM (NONO-AM), in inhibiting the growth and invasiveness of bone metastatic breast cancer cells.
  • Parental MDA-MB-231 breast cancer cells were resistant to 4-HPR-induced apoptosis at clinically relevant doses, whereas 4-HPR-induced apoptosis in a dose-dependent manner in MDA-MB-231/F10 bone metastatic breast cancer cells.
  • Unlike 4-HPR, NONO-AM induced apoptosis in a dose-dependent manner in both parental MDA-MB-231 cells and F10 cells.
  • The bone metastatic F10 cells were more sensitive to the anti-invasive effects of 4-HPR and NONO-AM than were MDA-MB-231 cells.
  • These in vitro results suggest that 4-HPR and NO pro-drugs may be effective chemopreventive agents against bone metastatic breast cancer.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Apoptosis / drug effects. Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Fenretinide / pharmacology. Nitric Oxide / physiology
  • [MeSH-minor] Dose-Response Relationship, Drug. Enzyme Induction. Female. Humans. Hydrazines / pharmacology. Neoplasm Invasiveness. Nitric Oxide Donors / pharmacology. Nitric Oxide Synthase / metabolism. Nitrogen Oxides / pharmacology. Tumor Cells, Cultured


87. Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P: Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol; 2008 Dec;39(12):1809-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
  • Bone is one of the most common sites of distant metastasis for breast carcinomas.
  • In this study, our objective is to identify molecular markers and molecular subtypes that may predict patients at higher risk of developing bone metastasis.
  • Immunohistochemical analysis with antibodies against estrogen receptor alpha, progesterone receptor, androgen receptor, Her2/neu, epidermal growth factor receptor, CK5/6, CK14, CK17, CK8, and CK18 was performed on representative sections of 21 breast carcinomas with bone metastasis and 94 cases without bone metastasis.
  • We found that (1) the breast cancers with bone metastasis were associated with a significant percentage of estrogen receptor-positive/progesterone receptor-negative tumors compared with tumors without bone metastasis (38% versus 6%, P < .0001). (2) There was significant difference on estrogen receptor expression between high grade and non-high grade in tumors with or without bone metastasis (P = .0084 and 1.0000, respectively). (3) The breast cancers with bone metastasis were more likely to be estrogen receptor positive (85%) and androgen receptor positive (95%) compared with those without bone metastasis (59% and 74%, respectively, both P < .05). (4) There was no significant difference between tumors with or without bone metastasis in subtype distribution (basal versus nonbasal) among all 3 molecular classifications. (5) Luminal B carcinomas of cytokeratin/triple negative classification tended to be associated with bone metastasis but not to a statistically significant extent.
  • In conclusion, bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative tumors.
  • Significant difference in estrogen receptor expression between high-grade and non-high-grade tumors with bone metastasis suggests that different panels of molecular markers should be used to predict bone metastasis in these 2 groups of tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / secondary. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adult. Cell Nucleus / metabolism. Cell Nucleus / pathology. Female. Humans. Immunoenzyme Techniques. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Predictive Value of Tests


88. Gálvez R, Ribera V, González-Escalada JR, Souto A, Cánovas ML, Castro A, Herrero B, de Los Angeles Maqueda M, Castilforte M, Marco-Martínez JJ, Pérez C, Vicente-Fatela L, Md CN, Orduña MJ, Padrol A, Reig E, Carballido J, Cózar JM: Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis. Patient Prefer Adherence; 2008;2:215-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis.
  • OBJECTIVES: A multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis.
  • MATERIALS AND METHODS: Males (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months.
  • Overall incidence of bone events was 11.2%.
  • Of the 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed satisfaction with the treatment DISCUSSION: Zoledronic acid is effective for reducing pain, improving mobility, and increasing the quality of life in patients with prostate cancer with bone metastasis.
  • Its easy administration and good tolerability make zoledronic acid one of the principal therapeutic tools in the management of patients with pain associated with bone metastasis from prostate cancer.

  • Andalusian Health Repository. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Feb;82(4):858-64 [10732759.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):6-14 [10618600.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2949-54 [10850442.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3015-21 [10898346.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3047-53 [10898350.001]
  • [Cites] Breast Cancer. 2000;7(4):361-9 [11114866.001]
  • [Cites] Cancer Treat Rev. 2001 Jun;27(3):165-76 [11417967.001]
  • [Cites] N Engl J Med. 2001 Sep 27;345(13):948-55 [11575286.001]
  • [Cites] J Urol. 2001 Dec;166(6):2023-31 [11696699.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68 [12359855.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):758-71 [12548573.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):879-82 [15173273.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):607-16 [15465464.001]
  • [Cites] Oncologist. 2005 Jan;10(1):52-62 [15632252.001]
  • [Cites] Oncology (Williston Park). 1992 Oct;6(10):37-43; discussion 43, 47-50 [1390013.001]
  • [Cites] Oncology (Williston Park). 1991 Aug;5(8):55-60; discussion 60-2, 65 [1834153.001]
  • [Cites] Br J Urol. 1991 Jul;68(1):74-80 [1873694.001]
  • [Cites] Cancer. 1993 Dec 1;72(11 Suppl):3443-52 [8242577.001]
  • [Cites] Cancer. 1993 Feb 1;71(3 Suppl):1131-7 [8428335.001]
  • [Cites] Drug Saf. 1996 Mar;14(3):158-70 [8934578.001]
  • [Cites] Hosp J. 1996;11(2):1-10 [8949010.001]
  • [Cites] J Urol. 1997 Feb;157(2):439-44 [8996327.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):545-50 [9028366.001]
  • [Cites] Semin Urol Oncol. 1997 Feb;15(1):28-32 [9050137.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1652-60 [9362432.001]
  • [Cites] Drug Saf. 1999 Nov;21(5):389-406 [10554053.001]
  • [Cites] Leukemia. 2000 May;14(5):841-4 [10803515.001]
  • (PMID = 19920966.001).
  • [ISSN] 1177-889X
  • [Journal-full-title] Patient preference and adherence
  • [ISO-abbreviation] Patient Prefer Adherence
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2770417
  • [Keywords] NOTNLM ; bone metastasis / pain / prostate cancer / zoledronic acid
  •  go-up   go-down


89. Ruggiero SL: Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin Cases Miner Bone Metab; 2007 Jan;4(1):37-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ).
  • Bisphosphonates are a class of agents used to treat osteoporosis and malignant bone metastases.
  • Despite these benefits, osteonecrosis of the jaws has recently emerged as a significant complication in a subset of patients receiving these drugs.
  • Based on a growing number of case reports and institutional reviews, bisphosphonate therapy may cause exposed and necrotic bone that is isolated to the jaw.
  • The pathogenesis for this complication appears to be related to the profound inhibition of osteoclast function and bone remodeling.
  • This report will review the clinical signs and symptoms and risks associated with this new complication and provide a guideline for establishing a stage-specific diagnosis of BRONJ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22460751.001).
  • [ISSN] 1724-8914
  • [Journal-full-title] Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
  • [ISO-abbreviation] Clin Cases Miner Bone Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2781180
  •  go-up   go-down


90. Abruzzese E, Iuliano F, Trawinska MM, Di Maio M: 153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opin Investig Drugs; 2008 Sep;17(9):1379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 153Sm: its use in multiple myeloma and report of a clinical experience.
  • BACKGROUND: In the past years the bone seeking radiopharmaceutical samarium lexidronam ((153)Sm-EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis.
  • OBJECTIVE: Its use has been explored in different solid tumours.
  • METHODS: (153)Sm-EDTMP has an affinity for bone and concentrates in areas of bone turnover.
  • It decays as a therapeutic beta-emission and at the same time as gamma-photon that can be used for tracking its concentration with bone scan imaging.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. Samarium, Elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18694370.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Isotopes; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium
  •  go-up   go-down


91. Liang JG, Jiang NY, DU JQ, Lu XP, Liu XG, Chen SX: [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. Zhonghua Zhong Liu Za Zhi; 2005 Mar;27(3):180-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
  • OBJECTIVE: To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis.
  • METHODS: Forty-eight patients with breast cancer with multi-bone metastases were randomly divided into three groups:15 patients received (188)Re-HEDP (group A), 15 patients received pamidronate (group B) and 18 patients were treated by (188)Re-HEDP plus pamidronate (group C).
  • RESULTS: The overall pain relief rate was 73.3%, 80.0%, 100.0% in groups A, B and C.
  • The response rate of bone metastasis was 40.0%, 33.3%, 66.7% in groups A, B and C respectively.
  • The therapeutic effect of group C was better than those of groups A and B (P < 0.05), without any significance in the difference (P > 0.05).
  • CONCLUSION: The therapeutic effect of (188)Re-HEDP combined with pamidronate for breast cancer with bone metastasis is remarkable in bone pain relief and bone metastasis control, which is better than either (188)Re-HEDP or pamidronate alone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Diphosphonates / therapeutic use. Etidronic Acid / therapeutic use. Organometallic Compounds / therapeutic use. Pain Management

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. 1-HYDROXY-1,1-DIPHOSPHONOETHANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946573.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Diphosphonates; 0 / Organometallic Compounds; 0 / Radioisotopes; 140709-07-5 / rhenium-186 HEDP; 7440-15-5 / Rhenium; M2F465ROXU / Etidronic Acid; OYY3447OMC / pamidronate
  •  go-up   go-down


92. Hoshi M, Takami M, Ieguchi M: Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. Radiat Med; 2008 Oct;26(8):499-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy.
  • We present a case of pleomorphic malignant fibrous histiocytoma arising from the left forearm in a 45-year-old man who had undergone resection and radiotherapy for a tumor 3 years previously.
  • At his first visit, he had multiple lung and bone metastases.
  • Although these metastases responded well to systemic chemotherapy, brain metastases newly appeared and caused the death of the patient.
  • These findings demonstrate that individual sarcomatous metastatic organs exhibit different sensitivities to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Brain Neoplasms / drug therapy. Histiocytoma, Malignant Fibrous / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Acetabulum. Bone and Bones / drug effects. Brain / drug effects. Doxorubicin / administration & dosage. Forearm. Humans. Ifosfamide / administration & dosage. Lung / drug effects. Male. Middle Aged


93. Lebret T, Di Palma M, Ripoll J, Méjean A: [Supportive care for urological metastatic patients]. Prog Urol; 2008 Nov;18 Suppl 7:S410-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supportive care for urological metastatic patients].
  • [Transliterated title] Les soins de support pour les patients souffrant d'un cancer urologique métastasé
  • Supportive cancer care is defined as "all the care and support necessary for the patient throughout the illness together with specific oncological treatment".
  • In urology, the example of patients with bone metastasis demonstrates the usefulness of this concept.
  • In fact it participates in: antalgic treatment, prevention of bone events (bisphosphonates), adaptation of daily life with a handicap, access to physiotherapy, psychological help.
  • [MeSH-minor] Home Care Services, Hospital-Based. Humans. Neoplasm Metastasis / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070824.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


94. Hu G, Kang Y, Wang XF: From breast to the brain: unraveling the puzzle of metastasis organotropism. J Mol Cell Biol; 2009 Oct;1(1):3-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From breast to the brain: unraveling the puzzle of metastasis organotropism.
  • Metastatic colonization of different target organs is a highly selective process that depends on specialized properties of tumor cells.
  • In a recent Nature paper, Massagué and colleagues built on their earlier success in functional genomic analysis of breast cancer metastasis to bone and lung and reported the identification of breast cancer brain metastasis genes, highlighting the importance of the stromal environment in the development of organ-specific metastasis.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633017.001).
  • [ISSN] 1759-4685
  • [Journal-full-title] Journal of molecular cell biology
  • [ISO-abbreviation] J Mol Cell Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Bhattacharyya S, Byrum S, Siegel ER, Suva LJ: Proteomic analysis of bone cancer: a review of current and future developments. Expert Rev Proteomics; 2007 Jun;4(3):371-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of bone cancer: a review of current and future developments.
  • The ability of sophisticated proteomic approaches to scrutinize the dynamic nature of protein expression, cellular and subcellular protein distribution, post-translational modifications, and protein-protein interactions has culminated in the identification of many potential new therapeutic targets and an abundance of cancer-related biomarkers.
  • From a proteomics perspective, amongst the most under-studied diseases are bone cancers, such as myeloma, osteosarcoma and breast and prostate cancer bony metastases.
  • This review focuses on the recent advances in proteomic technology that have thrust the skeletal cancer field into this exciting age of proteomics, and highlights the future work that is required to adapt this technology to specifically interrogate the skeletal consequences of malignancy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Neoplasms / metabolism. Proteomics / methods
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Female. Forecasting. Humans. Male. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17552921.001).
  • [ISSN] 1744-8387
  • [Journal-full-title] Expert review of proteomics
  • [ISO-abbreviation] Expert Rev Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 60
  •  go-up   go-down


96. Lara C, Borrero JJ, Porras V, Giraldez J: [Prostatic stromal sarcoma in a 20-year-old patient]. Arch Esp Urol; 2005 Nov;58(9):947-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic stromal sarcoma in a 20-year-old patient].
  • [Transliterated title] Sarcoma del estroma prostático en un paciente de 20 años de edad.
  • OBJECTIVE: Prostatic tumors are the most frequent malignant neoplasms in men, most of them being constituted by carcinomas; only 0.2% of malignant prostatic neoplasms are of mesenchimal origin.
  • METHODS AND RESULTS: We report the case of a 20 year-old man with a prostatic stromal sarcoma.
  • After total cystoprostatectomy a tumor measuring 8 cm could be seen, replacing almost the whole prostate.
  • Microscopically a spindle cell neoplasia with moderate atypia and a high mitotic index entrapping few elongated prostatic ducts (adopting a phyllodes tumor morphology) was observed.
  • Recurrences are not uncommon whereas lung and bone metastases have been described.
  • [MeSH-major] Prostatic Neoplasms / diagnosis. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430043.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 7
  •  go-up   go-down


97. Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, Fogelman I: The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging; 2010 Apr;37(4):706-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate.
  • PURPOSE: The purpose of this study was to investigate the additional value of single photon emission computed tomography/computed tomography (SPECT/CT) over whole-body planar bone scintigraphy and SPECT in prostate cancer patients in terms of diagnostic confidence, inter-reviewer agreement and the possible impact on the clinical management.
  • METHODS: This was a retrospective review of 40 consecutive prostate cancer patients (mean age 71 years) who underwent (99m)Tc-methylene diphosphonate (MDP) whole-body planar bone scintigraphy, SPECT and SPECT/CT between April 2006 and April 2008.
  • RESULTS: Fifty lesions on planar bone scintigraphy in the 40 patients were evaluated.
  • On reporting the SPECT/CT scans only 8% of lesions were rated as equivocal, 24% were rated as malignant and 68% as benign.
  • Weighted kappa scores for inter-reviewer agreement were 0.43 for bone scintigraphy, 0.56 for SPECT and 0.87 for SPECT/CT.
  • CONCLUSION: The addition of SPECT/CT resulted in a significant reduction of equivocal reports; a definitive diagnosis was given in the majority of the patients due to the improved diagnostic confidence compared to planar or SPECT imaging alone in prostate cancer patients with suspected bone metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Prostatic Neoplasms / pathology. Tomography, Emission-Computed, Single-Photon. Tomography, Spiral Computed
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Fractures, Compression / diagnosis. Humans. Male. Middle Aged. Observer Variation. Patient Care Planning. Retrospective Studies. Spinal Fractures / diagnosis. Spinal Neoplasms / diagnostic imaging. Spinal Neoplasms / secondary. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Prostate Cancer. 2003 Jun;2(1):41-5 [15046683.001]
  • [Cites] APMIS. 1989 Aug;97(8):689-98 [2669853.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23 (2):341-58 [12640151.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1102-6 [16818944.001]
  • [Cites] Eur J Nucl Med. 2000 Jun;27(6):721-6 [10901460.001]
  • [Cites] Radiology. 2006 Jan;238(1):264-71 [16304081.001]
  • [Cites] Cancer Invest. 1995;13(1):31-5 [7530590.001]
  • [Cites] AJR Am J Roentgenol. 2004 Sep;183(3):655-61 [15333352.001]
  • [Cites] AJR Am J Roentgenol. 2007 May;188(5):W467-74 [17449746.001]
  • [Cites] Nucl Med Commun. 2003 Jan;24(1):3-10 [12501015.001]
  • [Cites] Semin Nucl Med. 2006 Oct;36(4):286-94 [16950146.001]
  • [Cites] Radiology. 1993 Apr;187(1):193-8 [8451412.001]
  • (PMID = 20016889.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Raubenheimer EJ, Noffke CE: Pathogenesis of bone metastasis: a review. J Oral Pathol Med; 2006 Mar;35(3):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of bone metastasis: a review.
  • METHOD: A review of the literature was performed in order to provide a coherent overview on the pathogenesis of bone metastasis.
  • RESULTS: Bone metastasis follows complex molecular interactions that enable tumor cells to detach from the primary site, invade the extracellular matrix, intra-vasate, extra-vasate, and proliferate within bone.
  • They induce local bone changes that could manifest radiologically as either osteolytic or radiodense.
  • In addition to the direct bone changes, malignancies can elaborate mediators that are released in circulation, leading to generalized osteopenia.
  • CONCLUSIONS: The spread of malignant neoplasms to bone is not a random process but rather a cascade of specific molecular events orchestrated through complex interactions between neoplastic cells and their environment.
  • [MeSH-major] Bone Neoplasms / secondary. Insulin-Like Growth Factor Binding Proteins / metabolism. Neoplastic Cells, Circulating / pathology. Osteolysis / pathology
  • [MeSH-minor] Endothelium / physiopathology. Extracellular Matrix / enzymology. Humans. Neoplasm Metastasis / physiopathology. Osteoblasts / metabolism. Parathyroid Hormone-Related Protein / metabolism. Receptors, Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454807.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Parathyroid Hormone-Related Protein; 0 / Receptors, Transforming Growth Factor beta
  • [Number-of-references] 78
  •  go-up   go-down


99. Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, Aggarwal BB: Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway. Mol Cancer Res; 2010 Oct;8(10):1425-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway.
  • Most patients with cancer die not because of the tumor in the primary site, but because it has spread to other sites.
  • Common tumors, such as breast, multiple myeloma, and prostate tumors, frequently metastasize to the bone.
  • It is now well recognized that osteoclasts are responsible for the osteolysis observed in bone metastases of the tumor.
  • Receptor activator of NF-κB ligand (RANKL), a member of the tumor necrosis factor superfamily and an activator of the NF-κB signaling pathway, has emerged as a major mediator of bone loss, commonly associated with cancer and other chronic inflammatory diseases.
  • We investigated whether embelin could inhibit osteoclastogenesis-associated bone loss induced by RANKL and by tumor cells in vitro.
  • This benzoquinone also suppressed the osteoclastogenesis induced by multiple myeloma and by breast cancer cells.
  • Thus, embelin, an inhibitor of RANKL-induced NF-κB activation has great potential as a therapeutic agent for osteoporosis and cancer-linked bone loss.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2001 Mar;142(3):1290-5 [11181547.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2989-94 [10898342.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):78-84 [11437406.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30499-503 [11408488.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11581-6 [11562486.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3527-33 [11739153.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4615-21 [12393684.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1436-40 [12684416.001]
  • [Cites] Nature. 2003 May 15;423(6937):337-42 [12748652.001]
  • [Cites] Nat Rev Genet. 2003 Aug;4(8):638-49 [12897775.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5438-45 [14500379.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5547-53 [14607962.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3175-84 [15070700.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] Nat Med. 2004 Jun;10(6):617-24 [15156202.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):192-201 [15238139.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10137-42 [15220474.001]
  • [Cites] J Biol Chem. 2004 Sep 3;279(36):37219-22 [15252035.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):203-8 [15380510.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):677-90 [15505411.001]
  • [Cites] Chem Ber. 1972;105(2):614-24 [4645596.001]
  • [Cites] Indian J Physiol Pharmacol. 1977 Jan-Mar;21(1):31-9 [873589.001]
  • [Cites] Chemotherapy. 1994 Mar-Apr;40(2):109-13 [7510605.001]
  • [Cites] J Bone Miner Res. 1996 Feb;11(2):150-9 [8822338.001]
  • [Cites] Mol Pathol. 1997 Jun;50(3):132-7 [9292147.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3482-96 [9407039.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5 [10097072.001]
  • [Cites] Yao Xue Xue Bao. 1963 Sep;10:578-80 [14082600.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54841-8 [15485831.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):162-5 [15671541.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1677-87 [15897281.001]
  • [Cites] Int J Cancer. 2005 Aug 20;116(2):253-62 [15800904.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):169-80 [16025223.001]
  • [Cites] Immunol Rev. 2005 Dec;208:30-49 [16313339.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1221-8 [16489077.001]
  • [Cites] J Biol Chem. 2006 Jun 9;281(23):15809-20 [16613848.001]
  • [Cites] Mol Pharmacol. 2007 Jan;71(1):209-19 [17028156.001]
  • [Cites] Nat Med. 2007 Jan;13(1):62-9 [17159986.001]
  • [Cites] Mol Pharmacol. 2007 Jun;71(6):1703-14 [17387141.001]
  • [Cites] J Biol Chem. 2007 Jun 15;282(24):17340-50 [17439942.001]
  • [Cites] J Am Dent Assoc. 2008 Jan;139(1):23-30 [18167381.001]
  • [Cites] Clin Exp Metastasis. 2008;25(2):119-29 [18064531.001]
  • [Cites] J Bone Miner Res. 2008 Jun;23(6):826-36 [18558816.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2008 Aug;16(4):325-30 [18626250.001]
  • [Cites] J Dent Educ. 2008 Aug;72(8):919-29 [18676801.001]
  • [Cites] J Musculoskelet Neuronal Interact. 2008 Jul-Sep;8(3):204-16 [18799853.001]
  • [Cites] Morphologie. 2008 Dec;92(299):162-70 [19019718.001]
  • [Cites] Mol Cancer Ther. 2009 Aug;8(8):2339-47 [19671767.001]
  • [Cites] J Cell Biol. 2000 Jan 24;148(2):333-42 [10648566.001]
  • [Cites] Cancer Treat Rev. 2001 Jun;27(3):165-76 [11417967.001]
  • (PMID = 20826545.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA091844; United States / NCI NIH HHS / CA / P01 CA124787; United States / NCI NIH HHS / CA / CA-124787-01A2; United States / NCI NIH HHS / CA / CA-16 672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Bone Density Conservation Agents; 0 / NF-kappa B; 0 / RANK Ligand; 0 / TNFSF11 protein, human; SHC6U8F5ER / embelin
  • [Other-IDs] NLM/ NIHMS233648; NLM/ PMC2974017
  •  go-up   go-down


100. Tang X, Zhang Q, Shi S, Yen Y, Li X, Zhang Y, Zhou K, Le AD: Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer; 2010 Jan 1;126(1):90-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells.
  • Adjunctive chemotherapy with bisphosphonates has been reported to delay bone metastasis and improve overall survival in breast cancer.
  • In this study, we investigated the potential molecular mechanisms underlying the antiangiogenic effect of non-nitrogen-containing and nitrogen-containing bisphosphonates, clodronate and pamidronate, respectively, in insulin-like growth factor (IGF)-1 responsive human breast cancer cells.
  • We tested whether bisphosphonates had any effects on hypoxia-inducible factor (HIF)-1alpha/vascular endothelial growth factor (VEGF) axis that plays a pivotal role in tumor angiogenesis, and our results showed that both pamidronate and clodronate significantly suppressed IGF-1-induced HIF-1alpha protein accumulation and VEGF expression in MCF-7 cells.
  • Meanwhile, we found that the presence of pamidronate and clodronate led to a dose-dependent decease in the newly-synthesized HIF-1alpha protein induced by IGF-1 in breast cancer cells after proteasomal inhibition, thus, indirectly reflecting the inhibition of protein synthesis.
  • Consistently, we demonstrated that pamidronate and clodronate functionally abrogated both in vitro and in vivo tumor angiogenesis induced by IGF-1-stimulated MCF-7 cells.
  • These findings have highlighted an important mechanism of the pharmacological action of bisphosphonates in the inhibition of tumor angiogenesis in breast cancer cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 2008 Sep;83(9):1032-45 [18775204.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):851-64 [18846101.001]
  • [Cites] Mol Cancer Ther. 2008 Nov;7(11):3598-608 [18974394.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9712-22 [19047149.001]
  • [Cites] Nat Rev Cancer. 2008 Sep;8(9):705-13 [19143055.001]
  • [Cites] Oncogene. 2009 Jan 22;28(3):313-24 [18978810.001]
  • [Cites] Growth Horm IGF Res. 1999 Oct;9(5):280-9 [10543935.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Curr Med Chem. 2003 Jan;10(2):173-80 [12570716.001]
  • [Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):178-84 [12838321.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Science. 2003 Dec 12;302(5652):1975-8 [14671307.001]
  • [Cites] Int J Cancer. 2004 Oct 10;111(6):849-57 [15300796.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):698-705 [8698861.001]
  • [Cites] Sci Am. 1996 Sep;275(3):150-4 [8701285.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3322-31 [9345014.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Mol Cell Biochem. 1998 May;182(1-2):3-11 [9609109.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):364-71 [15455384.001]
  • [Cites] Int Immunopharmacol. 2005 Mar;5(3):461-83 [15683844.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):605-12 [15695405.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3257-63 [15833858.001]
  • [Cites] Ann Oncol. 2005 May;16(5):687-95 [15802276.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6548-54 [11522653.001]
  • [Cites] FEBS Lett. 2002 Feb 13;512(1-3):157-62 [11852072.001]
  • [Cites] Breast Cancer Res. 2002;4(1):18-23 [11879555.001]
  • [Cites] Breast Cancer Res. 2002;4(1):30-4 [11879557.001]
  • [Cites] Oncogene. 2008 Jan 17;27(4):540-7 [17653093.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Biochem Pharmacol. 2008 May 1;75(9):1858-67 [18329003.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1109-12 [18425365.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):933-41 [18507039.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1459-68 [10780527.001]
  • [Cites] Immunol Cell Biol. 2000 Aug;78(4):447-51 [10947872.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2211-21 [11092402.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):807-26 [11297505.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Cancer Treat Rev. 2001 Jun;27(3):165-76 [11417967.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1080-4 [12006522.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38205-11 [12149254.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48403-9 [12379645.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:443-7 [12485908.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4971-4 [15958534.001]
  • [Cites] Int J Cancer. 2005 Sep 20;116(5):734-9 [15849727.001]
  • [Cites] Mol Cell Endocrinol. 2005 Aug 30;240(1-2):23-31 [15978718.001]
  • [Cites] Oncology. 2005;69(1):35-43 [16088233.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1272-86 [16145048.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 14;342(3):851-8 [16499871.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6264-70 [16778202.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4506-14 [16899596.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4562-8 [16899602.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):25903-14 [16847054.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):739-49 [16954428.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9870-7 [17047048.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11263-70 [17145871.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):563-72 [17234764.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):1-12 [17237261.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):220-6 [17237281.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 9;354(2):478-84 [17240356.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1451-8 [17245699.001]
  • [Cites] Exp Cell Res. 2007 Mar 10;313(5):867-77 [17289019.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2568-76 [17473185.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4157-63 [17483326.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jun;103(2):167-75 [17028975.001]
  • [Cites] Oncogene. 2007 Jun 7;26(27):3920-9 [17213817.001]
  • [Cites] Biochem Pharmacol. 2007 Jul 15;74(2):191-201 [17498666.001]
  • [Cites] Cancer Treat Rev. 2008;34 Suppl 1:S25-30 [18486347.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4658-66 [18628481.001]
  • [Cites] Anticancer Res. 2008 May-Jun;28(3A):1551-7 [18630510.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):824-34 [18688034.001]
  • (PMID = 19569175.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA128099-02; United States / NIAMS NIH HHS / AR / S11 AR047359; United States / NCI NIH HHS / CA / R03 CA128099; United States / NCI NIH HHS / CA / R03 CA128099-02; United States / NIAMS NIH HHS / AR / 1S11 AR47359; United States / NIDCR NIH HHS / DE / R01 DE019932
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Diphosphonates; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Vascular Endothelial Growth Factor A; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS138042; NLM/ PMC2784023
  •  go-up   go-down






Advertisement